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Conclusion: Statin-related events occur commonly and often lead to
statin discontinuation. Most patients, however, when rechallenged with sta-
tins, are able to tolerate statins long-term.
Summary: Discontinuation of statin medications has been linked to
an increased risk for cardiovascular events and death in patients with coro-
nary artery disease (Rasmussen JN et al, JAMA 2007;297:177-86). In
reports of statin discontinuation, adverse reactions to statins are featured
prominently. However, in randomized, placebo-controlled, clinical trials,
statins are associated with only a slight increase in adverse reactions over
placebo and with no increase in discontinuation of treatment comparable
with placebo (Sacks FM et al, N Engl J Med 1996;355:1001-9). It is
unclear whether adverse symptomatology attributed to statins will reoccur
when a patient is rechallenged with a different statin or even with the
same statin at a later time. Given the potential adverse effects of statin
discontinuation, the authors sought to investigate reasons for statin discon-
tinuation and the role of statin-related events (clinical events or symptoms
believed to be caused by statins) in routine care settings. This was a retro-
spective cohort study involving patients from the Brigham and Women’s
Hospital and Massachusetts General Hospital in Boston. The study included
adults who received a statin prescription between January 1, 2000, and
December 31, 2008. Information regarding statin discontinuation was ob-
tained from a combination of electronic medical record review and analysis
of electronic provider notes by validated software. There were 107,835
patients identiﬁed as having been treated with statins. Statins were tempo-
rarily discontinued in 57,292 of these patients. In 18,778 (17.4%), statin-
related events were documented as the reason for discontinuation. Of these
patients, statins were discontinued at least temporarily in 11,124 patients,
and 6579 were rechallenged with a statin in the subsequent 12 months.
Most patients who were rechallenged (92.2%) were still taking a statin 12
months after the statin-related event. Of 2721 patients who were rechal-
lenged with the same statin to which they had a statin-related event,
1295 continued to receive that same statin 8 months later. In fact, 996
were receiving the same dose or a higher dose.
Comment: Events attributed to statins are common. However, the
data suggest most patients when rechallenged with statins can tolerate
them long-term, including patients rechallenged with the same statin that
led to their statin-related event! Perhaps statin-related events have other
causes than the medication itself, or are more tolerable, or more speciﬁc
to individual drugs than previously appreciated. At the very least, it seems
patients who are discontinued from statin medications deserve an attempt
to retry the same drug at a different dose or to be rechallenged with
a different statin.
Asymptomatic Carotid Artery Stenosis and the Risk of Ischemic Stroke
According to Subtype in Patients With Clinical Manifest Arterial
Disease
den Hartog A.G., Achterberg S., et al; the SMART Study Group. Stroke
2013;44:1002-7.
Conclusion: Patients with clinical arterial disease or type 2 diabetes
have a low risk of developing ischemic stroke, irrespective of subtype and
independent of the degree of asymptomatic carotid artery stenosis (ACAS).
Summary: In the general population, between 0% and 7.5% of asymp-
tomatic patients have $50% ACAS and between 0% and 3.1% have >70%
ACAS (de Weerd M et al, Stroke 2010;41:1294-7). A recent study of
patients with $50% ACAS and contralateral transient ischemic attacks or
stroke, who were on intensive medical therapy, demonstrated the average
annual risk of ipsilateral stroke or transient ischemic attack was 0.34%
(95% conﬁdence interval, 0.01-1.87; Marquardt L et al, Stroke
2010;41:e11-7). In this paper, the authors report their observations on
the development of ischemic stroke in patients with ACAS. This is
a secondary analysis of the Second Manifestations of Arterial Disease
(SMART) study. The SMART study is a single-center prospective cohort
study among patients referred to the University Medical Center in Utrecht
who have clinically manifest atherosclerotic disease or have risk factors for
atherosclerosis (Simons PC et al, Eur J Epidemiol 1999;15:773-81).
Patients in SMART are aged 18 to 79 years and initially undergo a standard-
ized vascular screening at baseline that includes a health questionnaire,laboratory assessment, and duplex ultrasound (DUS) imaging to investigate
for the prevalence of vascular disease. The patients are then followed up
prospectively. There are a total of 5866 SMART patients. Of these, 1473
had a history of cerebrovascular disease before their inclusion in SMART
or had missing DUS data. This left 4319 patients available for analysis in
this paper. No patient in the current analysis had a history of symptomatic
cerebrovascular disease. Carotid stenosis was evaluated with DUS imaging,
and strokes were classiﬁed during follow-up according to subtype as large
vessel or small vessel. Cox proportional hazard regression models were
used to evaluate the relationship between ACAS and future stroke. ACS
of 50% to 99% was present in 293 patients (6.8%), and of these, 193 had
70% to 99% ACAS. In these two subgroups, mean follow-up was 6.2 and
6.0 years, respectively. A total of 94 ischemic strokes occurred, eight of
which were in the 50% to 99% ACAS patients. The any-territory annual
ischemic stroke risk was 0.4% in 50% to 99% ACAS patients and 0.5% for
79% to 99% ACAS patients. Risk of ischemic stroke was not increased in
patients with 70% to 99% ACAS (hazard ratio [HR], 1.5; 95% conﬁdence
interval [CI], 0.7-3.5). There tended to be nonsigniﬁcantly more large-
vessel strokes in patients with 50% to 99% ACAS (HR, 1.5; 95% CI, 0.5-
4.2) than in patients with 70% to 99% ACAS (HR, 1.7; 95% CI, 0.5-5.6).
Comment: This is a strong study. The data were collected prospec-
tively, included a large number of patients, and patients were censored after
undergoing a carotid intervention. Follow-up was also longer compared
with much of the existing literature. The data appear concordant with the
emerging position that the natural history of ACAS with current medical
management is better than it used to be. The result is that interventions
for ACAS are coming under increasing question. The authors argue “for
a conservative approach in ACAS in general and revascularization only
within the conﬁnes of well-designed randomized clinical trials.”
n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group. N Engl J Med
2013;368:1800-8.
Conclusion: In patients with multiple cardiovascular risk factors, daily
treatment with n-3 fatty acids does not reduce cardiovascular mortality or
morbidity.
Summary: It has been suggested that n-3 polyunsaturated fatty acids
derived from ﬁsh reduce the risk of cardiovascular disease through beneﬁcial
effects on arrhythmias and atherosclerotic, inﬂammatory, and thrombotic
processes (De Caterina R, N Engl J Med 2011;364:2439-50). Indeed,
beneﬁt of n-3 fatty acids has been demonstrated to reduce cardiovascular
mortality and morbidity in patients surviving myocardial infarction and in
patients with heart failure (Lancet 1999;354:447-55 and Lancet
2008;372:1223-30). The current study, the Risk and Prevention Study,
was a double-blind, placebo-controlled trial to assess the efﬁcacy of n-3 fatty
acids in patients with multiple cardiovascular risk factors or atherosclerotic
vascular disease, but not myocardial infarction. Patients were chosen and fol-
lowed up by a network of 860 general practitioners in Italy and randomly
assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The prespeciﬁed
end point initially for the study was the cumulative rate of death, nonfatal
myocardial infarction, and nonfatal stroke. At 1 year, the event rate was
lower than anticipated; therefore, the primary end point was revised to
time to death from cardiovascular causes or admission to the hospital for
cardiovascular causes. The study enrolled 12,513 patients, and 6244 of
these were randomly assigned to n-3 fatty acids and 6269 to placebo.
Median follow-up was 5 years. The primary end point occurred in 1478
of the 12,505 patients included in the analysis. Of these, 733 of 6239
(11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received
placebo. The adjusted hazard ratio with n-3 fatty acids was 0.97 (95% conﬁ-
dence interval, 0.88-1.08; P ¼ .58). The same results were also observed for
secondary end points.
Comment: Fish oil appears to be joining an ever-expanding list of inef-
fective, but popular and well publicized, therapies for primary prevention of
cardiovascular disease. Consistent negative ﬁndings across the study prohibit
much in the way of alternative explanations for the data. However, the lower
event rate than expected, combined with the dietary habits of the Italian pop-
ulation and intensive exposure to other preventive treatments during the 5-
year follow-up period, may have inﬂuenced the results. It is also important
to note that these results do not negate the previously determined beneﬁts843
